GenMont Biotech Incorporation
TWSE:3164.TW
22.8 (TWD) • At close September 16, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) TWD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 318.015 | 368.546 | 427.929 | 325.191 | 346.244 | 406.532 | 552.941 | 540.78 | 534.719 | 564.525 | 308.937 | 226.821 | 286.214 | 514.577 | 352.848 |
| Cost of Revenue
| 140.679 | 111.829 | 128.603 | 109.801 | 116.543 | 128.985 | 231.27 | 230.696 | 261.433 | 311.175 | 94.904 | 82.675 | 94.436 | 121.144 | 70.657 |
| Gross Profit
| 177.336 | 256.717 | 299.326 | 215.39 | 229.701 | 277.547 | 321.671 | 310.084 | 273.286 | 253.35 | 214.033 | 144.146 | 191.778 | 393.433 | 282.191 |
| Gross Profit Ratio
| 0.558 | 0.697 | 0.699 | 0.662 | 0.663 | 0.683 | 0.582 | 0.573 | 0.511 | 0.449 | 0.693 | 0.636 | 0.67 | 0.765 | 0.8 |
| Reseach & Development Expenses
| 46.863 | 59.411 | 25.524 | 26.3 | 27.107 | 27.722 | 32.779 | 28.859 | 26.535 | 29.074 | 26.795 | 35.326 | 42.505 | 60.651 | 31.364 |
| General & Administrative Expenses
| 106.745 | 88.021 | 82.338 | 63.747 | 68.785 | 73.489 | 103.482 | 134.668 | 128.29 | 155.801 | 55.362 | 57.741 | 59.155 | 61.888 | 51.735 |
| Selling & Marketing Expenses
| 49.859 | 49.103 | 63.127 | 54.983 | 57.038 | 53.512 | 158.731 | 164.665 | 164.426 | 212.834 | 74.975 | 80.046 | 106.747 | 114.207 | 102.826 |
| SG&A
| 123.485 | 137.124 | 145.465 | 118.73 | 125.823 | 127.001 | 262.213 | 299.333 | 292.716 | 368.635 | 130.337 | 137.787 | 165.902 | 176.095 | 154.561 |
| Other Expenses
| 13.624 | 0.239 | 13.139 | 3.855 | -0.744 | 4.114 | 4.552 | -201.349 | -37.585 | -226.578 | 2.913 | -0.087 | -12.275 | 5.965 | 3.389 |
| Operating Expenses
| 170.348 | 196.535 | 170.989 | 145.03 | 152.93 | 154.723 | 294.992 | 328.192 | 319.251 | 397.709 | 157.132 | 173.113 | 208.407 | 236.746 | 185.925 |
| Operating Income
| 6.988 | 65.225 | 143.488 | 76.999 | 75.464 | 122.824 | 26.679 | -18.108 | -45.965 | -144.359 | 56.901 | -28.967 | -16.629 | 156.687 | 96.266 |
| Operating Income Ratio
| 0.022 | 0.177 | 0.335 | 0.237 | 0.218 | 0.302 | 0.048 | -0.033 | -0.086 | -0.256 | 0.184 | -0.128 | -0.058 | 0.304 | 0.273 |
| Total Other Income Expenses Net
| 21.175 | 1.033 | -4.064 | -0.152 | 0.076 | 1.079 | 4.552 | -201.349 | -37.585 | -236.672 | -20.044 | 62.377 | 60.444 | 7.28 | 6.506 |
| Income Before Tax
| 28.163 | 66.258 | 139.424 | 76.847 | 75.54 | 123.903 | 31.231 | -219.457 | -83.55 | -381.031 | 36.857 | 33.41 | 43.815 | 163.967 | 102.772 |
| Income Before Tax Ratio
| 0.089 | 0.18 | 0.326 | 0.236 | 0.218 | 0.305 | 0.056 | -0.406 | -0.156 | -0.675 | 0.119 | 0.147 | 0.153 | 0.319 | 0.291 |
| Income Tax Expense
| 5.732 | 18.797 | 29.823 | 16.632 | 18.305 | 25.805 | -13.752 | 16.481 | 14.478 | 5.127 | 5.966 | 13.59 | 5.451 | 8.129 | 10.623 |
| Net Income
| 32.991 | 56.978 | 113.132 | 60.884 | 57.451 | 158.019 | 45.6 | -235.938 | -98.028 | -386.158 | 30.891 | 28.89 | 38.159 | 147.542 | 86.234 |
| Net Income Ratio
| 0.104 | 0.155 | 0.264 | 0.187 | 0.166 | 0.389 | 0.082 | -0.436 | -0.183 | -0.684 | 0.1 | 0.127 | 0.133 | 0.287 | 0.244 |
| EPS
| 0.38 | 0.66 | 1.31 | 0.69 | 0.65 | 1.78 | 0.51 | -2.65 | -1.1 | -5.82 | 0.51 | 0.52 | 0.72 | 2.78 | 1.62 |
| EPS Diluted
| 0.38 | 0.66 | 1.3 | 0.69 | 0.64 | 1.77 | 0.51 | -2.65 | -1.1 | -5.82 | 0.51 | 0.52 | 0.72 | 2.78 | 1.62 |
| EBITDA
| 71.768 | 115.64 | 164.622 | 97.872 | 96.698 | 150.507 | 66.406 | 69.925 | 12.227 | -266.72 | 77.569 | 0.829 | 2.803 | 185.962 | 122.336 |
| EBITDA Ratio
| 0.226 | 0.314 | 0.385 | 0.301 | 0.279 | 0.37 | 0.12 | 0.129 | 0.023 | -0.472 | 0.251 | 0.004 | 0.01 | 0.361 | 0.347 |